Participants will take a daily film‑coated tablet for about 40 weeks and will attend regular clinic visits where blood samples are taken to measure HbA1c (a test that shows average blood sugar over the past few months), Fasting plasma glucose (blood sugar after not eating), and will record their own readings using self‑monitoring of blood glucose. Weight, systolic and diastolic blood pressure will also be checked. The study follows a double‑blind design, meaning neither the participants nor the researchers know which pill is being taken until the study ends.

The study is designed to continue treatment for patients who have already participated in previous research with rocatinlimab. Participants will receive either rocatinlimab or placebo through injections under the skin. This is a long-term study that will monitor how well patients maintain improvement in their skin condition and any side effects that may occur during treatment.

The research will track various aspects of the skin condition, including changes in skin appearance, itching severity, and overall symptoms. The study will particularly focus on monitoring the safety of the treatment by recording any side effects and checking laboratory test results and vital signs throughout the treatment period.

The purpose of the study is to see whether lunsekimig can reduce the number of moderate to severe flare‑ups of the lung disease over a year. After enrollment, participants will be randomly assigned to one of the two groups and will attend regular clinic visits for injections, safety checks, and simple breathing tests over several months.

A flare‑up, or exacerbation, means a sudden worsening of breathing problems that often requires extra medication or a hospital visit. The term Forced Expiratory Volume in 1 second refers to a common breathing test that measures how much air a person can force out of their lungs in one second; it helps doctors track lung function. The eosinophilic pattern is identified by a blood test that shows higher eosinophil counts, which can influence how the disease behaves and responds to treatment.

After the earlier treatment has finished, participants are assigned to receive either pumitamig or durvalumab. The study is randomized, which means the treatment is chosen by chance, and open-label, which means the treatment is known. The study team then follows the cancer over time and watches for changes, such as whether it stays stable, shrinks, or grows, and also checks how safe each medicine is and how well it is tolerated.

People in the study are assigned to one of the two medicines. The treatment is given over time as intravenous infusions, which means medicine is put directly into a vein. The study is double-blind, which means the people taking part and the study doctors do not know which treatment is being given. During the study, doctors follow how the cancer changes, watch for side effects, and check how well each medicine is tolerated.

Participants in this study will be assigned to receive either MET097 or a placebo. The study is designed to compare how much body weight changes over a specific period of time. During the course of the trial, individuals will receive their assigned treatment once every week. The process involves monitoring weight changes and other health factors over a long period, extending up to 84 weeks, to observe the impact of the medication on overall health.

One group will receive sotorasib combined with a platinum doublet, which refers to a combination of two drugs like carboplatin and pemetrexed. The other group will receive pembrolizumab along with the same platinum doublet. Other medications, such as folic acid, hydroxocobalamin, dexamethasone, and antiemetics, may be used to support the treatment and manage side effects. During the study, the time until the cancer grows or worsens and the total length of time patients live are monitored.

The treatments involve medications administered through an Intravenous line, which is a method of delivering medicine directly into a vein. One group receives the study drug PF-08634404 along with a combination of chemotherapy drugs, which may include Paclitaxel, Carboplatin, or Pemetrexed. Another group receives Pembrolizumab combined with these chemotherapy drugs. Some participants may also receive Paclitaxel Albumin-Bound or a Placebo involving Sodium Chloride. During the study, participants will be monitored to see how they respond to the medicines and to track their Overall Survival and Progression-Free Survival, which refers to the length of time during and after treatment that a person lives with the disease without it getting worse.

Participants will be compared against two other options. One option is Trimbow, which contains the same three active ingredients. The other comparison involves using beclometasone dipropionate alone. Some individuals may also receive a placebo. The study uses a cross-over design, meaning that participants will receive different treatments at different times during the course of the study to see how each one affects their breathing.

One of the main ways the study looks at how well the medicine works is by measuring the forced expiratory volume in 1 second, which is a test that calculates how much air a person can exhale quickly to check lung function. The study tracks these changes over a period of time to see how the different inhaled medications affect breathing capacity and overall control of the condition.

The purpose of the study is to compare the effectiveness of different medication combinations in preventing the cancer from getting worse. One group will receive a combination of sotorasib, panitumumab, and FOLFIRI. FOLFIRI is a treatment plan that includes fluorouracil, irinotecan hydrochloride trihydrate, and calcium folinate, all of which are administered through intravenous use, meaning they are delivered directly into a vein. Another group will receive FOLFIRI either alone or combined with bevacizumab.

Participants will be assigned to one of these treatment groups to see which approach is better at managing the disease. The study will follow the progress of the cancer over time to observe how long the treatments keep the disease from spreading further or increasing in size.

The cancer being investigated is also classified as advanced or metastatic, meaning it has grown beyond the original part of the lung or has spread to other parts of the body. Participants in this trial will receive their treatment through intravenous use, which involves delivering the medication directly into a vein using a liquid solution for infusion. The study will monitor how long the cancer remains stable without growing and the overall length of time patients live during the trial.

This clinical trial is focused on studying treatments for Stage IV non-small cell lung cancer (NSCLC), a type of lung cancer that has spread to other parts of the body. The study will explore the effectiveness and safety of different treatment combinations. One of the main treatments being tested is pembrolizumab, also known by its code name MK-3475. Pembrolizumab is a type of medication that helps the immune system fight cancer cells. Other treatments being studied in combination with pembrolizumab include patritumab deruxtecan (code name MK-1022), paclitaxel, pemetrexed disodium, carboplatin, and paclitaxel albumin-bound.

The purpose of this study is to evaluate how well these treatment combinations work and how safe they are for patients. Participants will receive these treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor the participants’ response to the treatments and any side effects they may experience. The goal is to find the most effective and safe treatment options for patients with Stage IV NSCLC.

Throughout the study, researchers will assess the Objective Response Rate (ORR), which measures how well the cancer responds to the treatment. They will also track the number of participants who experience side effects and those who may need to stop the treatment due to these effects. Additionally, the study will look at the Duration of Response (DOR), Progression-Free Survival (PFS), and Overall Survival (OS) to understand the long-term benefits of the treatments. This research aims to improve treatment options for patients with advanced lung cancer.

People taking part in this study will be adults aged 40 years or older who have moderate to severe plaque psoriasis and who have at least one risk factor that may affect heart health, such as smoking, high blood pressure, high cholesterol, diabetes, obesity, or a family history of heart disease. During the study, participants will receive either deucravacitinib or ustekinumab for up to 60 months. The study will monitor for various heart and blood vessel problems, including heart attacks, strokes, procedures to open blocked blood vessels in the heart, blood clots in the legs or lungs, and heart failure requiring hospital care.

Throughout the study, participants will have regular check-ups that include blood tests to check liver function and cholesterol levels. The study will also track other safety concerns such as serious side effects, infections, and skin cancers. Information will be collected about any side effects that lead to stopping the medication and about deaths from any cause. This study is designed to run for several years to understand the long-term safety of these treatments in people with psoriasis who have risk factors for heart disease.

Participants in this study will be adults between 18 and 90 years old who have experienced a stroke within the past 24 hours. The treatment will be given over a period of 21 days. During the study, participants will have various health checks including physical examinations, blood tests, heart monitoring with an electrocardiogram, and measurements of vital signs such as blood pressure, heart rate, breathing rate, and body temperature. These checks will happen at different times during the study, including on days 1, 4, 21, and 90.

The main goal of the study is to measure how well participants recover from their stroke by day 90, which will be assessed using a scale called the modified Rankin Score that measures how well people can function in their daily activities. The study will also carefully track any side effects or unwanted reactions that participants may experience, including reactions at the injection site. Additional measurements will look at how independent participants are in performing daily activities, their neurological recovery, and whether they experience another stroke during the 90-day study period.

The study involves two groups of participants – one receiving rocatinlimab injections under the skin along with topical treatments, and another receiving placebo injections with the same topical treatments. The treatment period lasts for 24 weeks, during which the effectiveness of the medication will be evaluated by examining improvements in skin appearance and reduction in disease severity.

Throughout the study, doctors will monitor how well the treatment works by checking if participants’ skin becomes clearer and if their symptoms, such as itching and skin pain, improve. They will pay special attention to how the treatment affects different areas of the body, including the face and hands, in people who have atopic dermatitis in these locations.

The study involves taking either TAK-279, apremilast, or placebo in the form of tablets that are swallowed. During the study, doctors will monitor how well the medications work by examining changes in the skin’s appearance and the extent of psoriasis coverage on the body. They will look at improvements in skin clearance and reduction in psoriasis symptoms.

The research will include periods where some participants may switch between different treatments to better understand how the medication works over time. The study will track various aspects of psoriasis, including how it affects the scalp, nails, hands, and feet. Participants will be monitored for approximately 60 weeks to evaluate both the effectiveness and safety of the treatment.

The purpose of this research is to test how safe bemarituzumab is and how well it works in treating different types of solid tumors. The study is divided into two parts. In the first part, doctors will closely monitor how patients respond to the medication and any side effects that may occur. In the second part, they will evaluate how effective the medication is at fighting the cancer.

During the study, patients will receive bemarituzumab through regular infusions. The doctors will track the progress of the treatment using different medical tests and imaging scans such as computed tomography (CT) or magnetic resonance imaging (MRI). They will monitor how the tumors respond to the treatment and keep track of any changes in the patient’s health throughout the study period.

The purpose of the study is to determine how effective REGN7508 is at preventing blood clots after knee replacement surgery when compared to the standard treatments. The medication will be given either through an intravenous injection into a vein or as an injection under the skin. Some patients will receive apixaban tablets to take by mouth, while others will receive enoxaparin as an injection under the skin.

During the study, doctors will monitor patients for signs of blood clots and bleeding. They will also check how well the body tolerates the new medication and whether the body develops any response to it. The study will look for different types of blood clots, including deep venous thrombosis (blood clots in deep veins) and pulmonary embolism (blood clots in the lungs).

The study will last 30 weeks, during which participants will take their assigned medication once daily by mouth. The medications come in different forms – RO7795081 as hard capsules and Rybelsus as tablets. The study will measure changes in HbA1c (a measure of average blood sugar levels over the past few months) and body weight, among other health indicators.

Throughout the study period, participants will need to visit the clinic regularly for health check-ups. These visits will include blood tests to measure blood sugar control, body weight measurements, and monitoring for any side effects. The study is designed as a double-blind trial, which means neither the participants nor most of the healthcare providers will know which treatment each person is receiving.

The purpose of this research is to determine if using THIO followed by cemiplimab helps patients with advanced NSCLC live longer compared to using standard chemotherapy alone. Both treatments are given through an intravenous infusion, which means the medication is delivered directly into the bloodstream through a vein.

During the study, patients will be randomly assigned to receive either the THIO/cemiplimab combination or one of the standard chemotherapy medications. The treatment period may continue for up to 24 months. Throughout the study, doctors will monitor patients’ health and track how their cancer responds to the treatment. They will also watch for any side effects that may occur during the treatment period.

The treatment involves taking AP31969 tablets orally for a period of 12 weeks. The medication will be provided as film-coated tablets in various dosage strengths. Some participants will receive the active medication, while others will receive placebo tablets that look identical to the real medication but contain no active substance.

During the study, participants will have their heart rhythm monitored continuously through special recording devices. The study will track how often atrial fibrillation episodes occur and how long they last. Participants will also complete questionnaires about their quality of life and symptoms related to their heart condition.

The purpose of this research is to determine how well AZD0780 works compared to placebo in lowering LDL cholesterol levels after 12 weeks of treatment. The medication comes as a film-coated tablet that is taken by mouth. Some participants will receive AZD0780, while others will receive a placebo.

The study will last for 52 weeks (one year), during which participants will continue taking their regular cholesterol-lowering medications. Throughout the study, researchers will measure various types of cholesterol and other blood fats, including apolipoprotein B, non-HDL cholesterol, and lipoprotein(a), to understand how well the treatment works.

The main purpose of this study is to determine how well these treatments work in fighting lung cancer and to evaluate their safety when used individually. The medications will be administered over a period of up to 24 months, with different dosing schedules for each drug. Raludotatug Deruxtecan will be given at doses up to 5.6 mg per kilogram of body weight, Ifinatamab Deruxtecan at doses up to 12 mg per kilogram, and Docetaxel at doses up to 75 mg per square meter of body surface area.

During the study, doctors will monitor how the cancer responds to treatment and track any side effects that may occur. The study will measure how many patients’ tumors shrink or disappear, how long the treatment effects last, how long patients live without their cancer getting worse, and overall survival time. This research is part of a larger study called KEYMAKER-U01, which is investigating various treatment options for lung cancer.

The purpose of this research is to evaluate how well these treatments work in treating advanced non-squamous non-small cell lung cancer and to assess their safety. The study specifically includes patients whose cancer has progressed after receiving both platinum-based chemotherapy and immunotherapy treatments. The treatment period may last up to 24 months, during which patients will receive regular doses of one of the study medications.

Throughout the study, participants will undergo regular medical evaluations to monitor their response to treatment and any side effects. The research team will track various aspects of the participants’ health, including how the tumor responds to treatment, how long the response lasts, and how long patients survive without their disease getting worse. The study will use specialized imaging to measure changes in tumor size and assess the effectiveness of the treatment.

The purpose of the study is to assess how well tildrakizumab works in reducing the symptoms of genital psoriasis over a period of 16 weeks. Participants will be randomly assigned to receive either the medication or the placebo, and neither the participants nor the researchers will know who is receiving which treatment. This is known as a double-blind study. The main goal is to see if tildrakizumab can help clear the skin or significantly reduce the severity of the psoriasis compared to the placebo.

Throughout the study, participants will have regular check-ups to monitor their progress and any side effects. The study will last for a total of 52 weeks, allowing researchers to gather comprehensive data on the long-term effects and safety of tildrakizumab. This research aims to provide valuable insights into the treatment of moderate to severe genital psoriasis and potentially improve the quality of life for those affected by this condition.

Participants in the study will receive either the new medication, Ustekinumab, or a placebo. The new medication, JNJ-77242113, is taken as a film-coated tablet, while Ustekinumab is given as an injection. The study will last for several weeks, during which participants will be monitored to see how their psoriasis responds to the treatment. The goal is to see if the new medication can improve the symptoms of psoriasis, such as reducing the size and severity of the skin patches.

The study will involve regular check-ups to assess the condition of the skin and overall health. Participants will be randomly assigned to one of the treatment groups, and neither the participants nor the researchers will know which treatment is being given to ensure unbiased results. The study aims to provide valuable information on whether JNJ-77242113 is a safe and effective option for treating moderate to severe plaque psoriasis.

The purpose of the study is to evaluate the safety and effectiveness of BNT327 when used with chemotherapy. The trial is divided into two phases: Phase II and Phase III. In Phase II, the focus is on assessing how safe and tolerable BNT327 is at different dose levels when combined with chemotherapy. In Phase III, the study will compare the effectiveness of BNT327 combined with chemotherapy to the combination of pembrolizumab and chemotherapy. The study will also look at how these treatments affect the progression of the disease and overall survival of participants.

Participants in the study will receive treatment over a period of time, with regular follow-up visits to monitor their health and the effects of the treatment. The study aims to provide valuable information on the potential benefits and risks of using BNT327 in treating non-small cell lung cancer, which could lead to new treatment options for patients in the future.

Participants in the study will receive ESK-001, which is taken as a tablet by mouth. Some participants may receive a placebo, which looks like the medication but does not contain the active ingredient. The treatment period can last up to 48 weeks, and the study will monitor how patients respond to the medication over this time. The goal is to see if ESK-001 can help reduce the symptoms of plaque psoriasis and maintain these improvements.

The study will also look at the quality of life of participants, assessing changes in their daily living and comfort levels. By the end of the study, researchers hope to gather valuable information on the long-term use of ESK-001 for treating moderate to severe plaque psoriasis, which could help in managing the condition more effectively in the future.

Participants in the study will be randomly assigned to receive either the combination of Baxdrostat and Dapagliflozin, Dapagliflozin alone, or a placebo. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving which treatment. The study will continue until a certain number of heart failure events or cardiovascular deaths occur among the participants, which will help determine the effectiveness of the treatments being tested.

The trial will involve taking the medications in the form of tablets, which are to be taken orally. The study is designed to last for a maximum of 38 weeks. Participants will be monitored throughout the study to assess the occurrence of heart failure events, hospitalizations, and any cardiovascular-related deaths. The results of this study will help to understand the potential benefits of using Baxdrostat in combination with Dapagliflozin for individuals at risk of heart failure.

Participants in the study will be randomly assigned to receive either the combination of Baxdrostat and Dapagliflozin or Dapagliflozin with a placebo. A placebo is a substance with no active medication. The study will be conducted in a way that neither the participants nor the researchers know who is receiving which treatment, ensuring unbiased results. The treatment period will last up to 60 days, and participants will take the medication in the form of tablets.

The study aims to monitor the health of the participants over time, focusing on changes in kidney function and heart health. The researchers will look for any significant decline in kidney function, the need for dialysis or kidney transplant, and any heart-related deaths. The study will also track changes in blood pressure and other health markers. This research hopes to provide valuable insights into better treatment options for people with CKD and high blood pressure.

The purpose of the study is to evaluate how well JNJ-77242113 works in reducing the signs and symptoms of psoriatic arthritis in people who have previously been treated with other biological medications. The study will last for several weeks, during which participants will take the medication and have regular check-ups to monitor their condition and any changes in their symptoms.

Participants will be randomly assigned to receive either the active medication or the placebo, and neither the participants nor the researchers will know who is receiving which treatment. This is known as a double-blind study, which helps ensure that the results are not biased. The main goal is to see if the medication can help improve the condition by Week 16, as measured by a standard response used in rheumatology studies.

The purpose of the study is to assess how effective and safe JNJ-77242113 is in reducing the signs and symptoms of psoriatic arthritis. The study will compare the effects of this medication to a placebo, which is a substance with no active drug. Participants will receive either the medication or the placebo and will be monitored over a period of time to see how their symptoms change.

During the study, participants will receive the treatment for up to 100 weeks. The medication will be administered in different doses, and the effects will be evaluated at various points, including at 16 weeks. The study aims to provide valuable information on whether JNJ-77242113 can be a beneficial treatment option for those suffering from active psoriatic arthritis.

The purpose of the study is to determine if ESK-001 is more effective than a placebo after 16 weeks of treatment. Participants will be randomly assigned to receive either ESK-001, Otezla, or a placebo. The study will last up to 24 weeks, during which participants will take the medication orally. The trial aims to see improvements in the skin condition by measuring changes in the severity and extent of the psoriasis patches.

Throughout the study, participants will be monitored to assess the safety and effectiveness of the treatments. The trial will help researchers understand if ESK-001 can provide better outcomes for people with moderate to severe plaque psoriasis compared to existing treatments. This study is an important step in finding new and effective ways to manage this chronic skin condition.

During the study, participants will receive either sonelokimab at different doses, risankizumab, or placebo through subcutaneous injection. The medications work by targeting specific proteins in the body that cause inflammation. The main focus will be on checking if sonelokimab helps reduce joint symptoms after 16 weeks of treatment.

The study will monitor how the medications affect both joint pain and skin symptoms associated with psoriatic arthritis. Participants will have regular check-ups to assess their response to treatment and to monitor their overall health. The medications being tested are designed to help reduce inflammation and improve symptoms in people whose condition has not improved enough with other treatments called TNF-alpha inhibitors.

The purpose of the study is to evaluate the effectiveness of LY4100511 in reducing the symptoms of plaque psoriasis. Participants in the study will be randomly assigned to receive either the active medication or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for up to 12 weeks, during which participants will take the medication in tablet form by mouth. Throughout the study, participants will have regular check-ups to monitor their condition and any changes in their symptoms.

By the end of the study, researchers aim to determine how well LY4100511 works in improving the skin condition of those with moderate-to-severe plaque psoriasis. The study will also gather information on the safety of the medication and any side effects that may occur. This research is important for developing new treatments that can help manage plaque psoriasis more effectively.

Participants in the study will take Zasocitinib in the form of a film-coated tablet, which is taken orally once a day. The study will monitor participants over a period of time to observe any side effects or changes in their condition. The study aims to see if the medication can help improve the symptoms of plaque psoriasis, such as reducing the size and severity of the skin patches.

Throughout the study, researchers will keep track of any adverse events, which are any unwanted effects that occur while taking the medication. They will also look for improvements in the condition, such as a significant reduction in the psoriasis area and severity. The study is designed to provide valuable information about the long-term use of Zasocitinib for treating moderate-to-severe plaque psoriasis.

The purpose of this research is to determine if tozorakimab can reduce the frequency of COPD flare-ups (also called exacerbations) when added to regular COPD treatments. During the study, some participants will receive tozorakimab while others will receive a placebo, in addition to their regular COPD medications. The study will particularly focus on people who previously smoked and have experienced COPD flare-ups in the past.

The treatment period will last for approximately one year, during which participants will receive regular injections of either tozorakimab or placebo. Throughout the study, participants will continue using their regular COPD medications, including inhalers. The study will monitor how often participants experience COPD flare-ups and track changes in their breathing and overall health.

Participants in the study will receive the treatments through an intravenous infusion, which means the medicine is given directly into a vein. The study will take place over a period of up to 12 months. During this time, doctors will monitor the patients to see how the cancer responds to the treatment and to check for any side effects. Some patients may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatments.

The study aims to find out if the treatments can help achieve a complete response, meaning no cancer cells are found after surgery. It will also look at how long patients remain free of cancer after treatment and surgery. The results will help determine if these treatments can be a safe and effective option for people with early-stage .

The purpose of the study is to compare the effectiveness and safety of the combination of Capivasertib and Docetaxel against a combination of a placebo and Docetaxel in treating patients with mCRPC. A placebo is a substance with no active drug, used to compare the effects of the actual drug. Participants in the study will be randomly assigned to receive either the Capivasertib and Docetaxel combination or the placebo and Docetaxel combination. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving the actual drug combination or the placebo combination.

Throughout the study, participants will receive regular treatments and will be monitored closely by the research team. The main goal is to assess the overall survival of patients, which refers to the length of time from the start of the study until death from any cause. The study will also look at other factors such as the progression of the cancer, changes in pain levels, and any side effects experienced by the participants. The study is expected to continue until December 2026, with the aim of providing valuable information on the potential benefits of Capivasertib in combination with Docetaxel for treating mCRPC.

Participants in the study will be randomly assigned to receive either CHF6001 DPI or a placebo, which is a substance with no active medication. The study will last for 52 weeks, during which participants will continue their regular maintenance therapy while also using the study medication. The main goal is to see if CHF6001 DPI can reduce the number of moderate and severe flare-ups of COPD and Chronic Bronchitis compared to those who receive the placebo. Throughout the study, participants will be monitored for any changes in their condition and any side effects they may experience.

By the end of the study, researchers aim to gather information on how CHF6001 DPI affects the overall health and quality of life of individuals with COPD and Chronic Bronchitis. This includes looking at changes in symptoms, lung function, and the need for additional medication. The findings from this study could help improve treatment options for people living with these chronic respiratory conditions.